Results 181 to 190 of about 889,258 (299)

A genome-wide MAGIC kit for recombinase-independent mosaic analysis in <i>Drosophila</i>. [PDF]

Elife
Shen Y, Yeung AT, Ditchfield P, Korn E, Clements R, Chen X, Wang B, Huang Z, Sheen M, Jarman PA, Han C.   +10 more
europepmc   +1 more source

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Toll receptors mediate tissue intrinsic surveillance against aberrant cells by detecting cell fate aberrations. [PDF]

Development
Frey A, Ernst L, Fischer F, Alpar L, Bellaïche Y, Classen AK.   +5 more
europepmc   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Pre-existing TCR clones drive major pathological responses in HNSCC patients treated with dual immune checkpoint inhibitors. [PDF]

Clin Cancer Res
Ge H, Li H, Kulkarni A, Chen Z, Upadhyay P, Ferris RL, Wang JH.   +6 more
europepmc   +1 more source

Cloning questions [PDF]

Nature Genetics, 1997
openaire   +2 more sources

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer. [PDF]

Cancer Res
Jiménez-Sánchez A, Persad S, Hayashi A, Umeda S, Sharma R, Xie Y, Mehta A, Park W, Masilionis I, Chu T, Zhu F, Hong J, Chaligne R, O'Reilly EM, Mazutis L, Nawy T, Pe'er I, Iacobuzio-Donahue CA, Pe'er D.   +18 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

EpCAM supports exit from pluripotency of embryonic stem cells via Eomes. [PDF]

Cell Death Dis
Gong N, Gouda M, Balaz AM, Song J, Kranz G, Hess J, Baumeister P, Unger K, Katalina V, Canis M, Gires O.   +10 more
europepmc   +1 more source